A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.

The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.

Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.

Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.

Ocular toxicities could be the reason.

Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.

Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.

The company will start a phase 2/3 trial of its Mirati-originated PRMT5 inhibitor in autumn.

Adverse events will be closely watched when full data are reported.